Welcome to our dedicated page for Pyxis Oncology SEC filings (Ticker: PYXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Pyxis Oncology, Inc. filings document a clinical-stage oncology company developing MICVO, an investigational antibody-drug conjugate for difficult-to-treat cancers. Its 8-K reports cover financial results, corporate updates, Regulation FD presentations, clinical data disclosures, and trial-related updates for MICVO in recurrent or metastatic head and neck squamous cell carcinoma and other advanced solid tumors.
The company’s regulatory record also includes proxy materials for annual meeting matters, director elections, governance proposals, executive transitions, employment and separation arrangements, equity compensation matters, and emerging growth company status. These filings describe Pyxis Oncology’s public-company governance, program disclosures, capital-related arrangements, and risk-linked clinical development reporting.
GordonMD Global Investments LP and related entities filed an initial ownership report for Pyxis Oncology, Inc.. Through GordonMD Long Biased Master Fund LP, they report indirect holdings of 10,024,909 shares of common stock. They also report a Common Stock Purchase Warrant directly held for up to 4,900,039 underlying shares at an exercise price of $3.289 per share, expiring on July 2, 2029. The warrant becomes exercisable on the earlier of the Issuer’s first public disclosure of clinical data from its MICVO Phase 1 monotherapy study in 2L+ R/M HNSCC or October 1, 2026. The Master Fund, its general partner, and Craig D. Gordon each disclaim beneficial ownership beyond any pecuniary interest.
Pyxis Oncology, Inc. has a significant shareholder group led by Biotechnology Value Fund entities and Mark N. Lampert. As of the close of business on July 10, 2026, these reporting persons and a managed account held an aggregate of 7,840,062 Warrants exercisable for 7,840,062 shares of common stock at an exercise price of $3.289 per share, expiring on July 2, 2029. A 9.99% beneficial ownership limitation caps immediate exercisability to 496,840 of these shares. Based on an adjusted share-count denominator that includes previously outstanding shares, shares issued under a June 30, 2026 Securities Purchase Agreement, and the 496,840 issuable shares, BVF beneficially owned 4,611,887 shares (approximately 5.5% of the class), BVF II 3,083,847 shares (approximately 3.7%), and the trading fund 518,280 shares (less than 1%). Through layered general partner and investment manager relationships, BVF Partners L.P., BVF Inc., and Mr. Lampert may each be deemed to beneficially own approximately 9.99% of the outstanding shares, subject to the ownership cap, while various entities expressly disclaim beneficial ownership of securities held by affiliated funds.
Pyxis Oncology director Jakob Dupont reported an exercise-and-sale of company stock. He exercised stock options covering 35,000 shares of common stock at an exercise price of $1.60 per share and received the underlying shares.
On the same date, he sold 35,000 common shares in open-market transactions at a weighted average price of $3.06 per share, with trade prices ranging from $3.00 to $3.36. These sales were carried out under a pre-arranged Rule 10b5-1 trading plan. After the transactions, Dupont holds 38,741 shares of Pyxis Oncology common stock directly.
Pyxis Oncology, Inc. entered into definitive securities purchase agreements for a private placement of 19,600,153 shares of common stock at $2.551 per share, together with common warrants to purchase an equal number of shares at an exercise price of $3.289. The deal is expected to provide approximately $50 million in upfront gross proceeds and up to an additional $64 million if the warrants are exercised for cash. Management expects this funding to extend the company’s cash runway into the second quarter of 2027 and to support development of its lead cancer therapy MICVO through key Phase 1 and Phase 1/2 clinical milestones, with updated monotherapy data planned for Fall 2026 and combination data in the fourth quarter of 2026. Pyxis also granted investors registration rights to resell the shares and warrant shares.
Pyxis Oncology, Inc. ownership disclosure shows GordonMD-related reporting persons each beneficially hold 10,024,909 shares of Common Stock, representing 12.1% of the class as reported. The filing lists shared voting and dispositive power of 10,024,909 shares and includes standard disclaimers about beneficial ownership.
Pyxis Oncology, Inc. held its Annual Meeting of Stockholders in virtual format on June 15, 2026. As of the April 20, 2026 record date, 62,855,464 shares of common stock were outstanding and entitled to vote. A quorum was present, with 47,302,035 shares represented virtually, in person or by proxy.
Stockholders elected three Class II directors—Thomas Civik, Freda Lewis-Hall, M.D., and Michael A. Metzger—to serve until the 2029 annual meeting and until their successors are elected and qualified. Support levels varied by nominee, with for votes ranging from 19,188,755 to 27,341,415.
Stockholders also ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, with 46,203,257 votes for, 1,076,997 against and 21,781 abstentions.
Pyxis Oncology reported a net loss of $23.3 million for the quarter ended March 31, 2026, slightly higher than the $21.2 million loss a year earlier, as it increased spending on its lead cancer drug candidate MICVO.
Research and development expenses rose to $20.0 million, driven mainly by higher clinical trial and preclinical costs for MICVO monotherapy and combination studies. General and administrative expenses fell to $4.4 million, largely due to lower stock-based compensation.
Pyxis ended the quarter with $41.0 million in cash, cash equivalents and marketable debt securities and an accumulated deficit of $466.4 million. Management states there is substantial doubt about the company’s ability to continue as a going concern beyond the next 12 months without additional financing, despite having an effective $350.0 million shelf registration and $150.0 million at-the-market capacity.
Pyxis Oncology, Inc. reported first quarter 2026 results and highlighted progress in its lead antibody-drug conjugate, micvotabart pelidotin (MICVO), for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC).
Updated MICVO Phase 1 monotherapy data in 2L+ R/M HNSCC are planned for mid‑2026, focusing on patients treated at or below a dose cap introduced in December 2025, while updated Phase 1/2 combination data with KEYTRUDA in 1L R/M HNSCC are expected in the second half of 2026. The company also presented supportive preclinical data at the 2026 AACR meeting and completed target enrollment in the Phase 1 monotherapy dose expansion study.
Financially, Pyxis Oncology reported a Q1 2026 net loss of $23.3 million, or ($0.37) per share, compared with a net loss of $21.2 million, or ($0.35) per share, a year earlier. Research and development expenses rose to $20.0 million, while general and administrative expenses declined to $4.4 million. The company ended March 31, 2026 with $42.5 million in cash, cash equivalents, restricted cash, and short‑term investments and expects this to fund operations into the fourth quarter of 2026.